Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Liabilities: 2009-2025

Historic Total Liabilities for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $902.3 million.

  • Ani Pharmaceuticals' Total Liabilities rose 5.34% to $902.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $902.3 million, marking a year-over-year increase of 5.34%. This contributed to the annual value of $855.2 million for FY2024, which is 91.39% up from last year.
  • Ani Pharmaceuticals' Total Liabilities amounted to $902.3 million in Q3 2025, which was up 2.38% from $881.4 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Total Liabilities' 5-year high stood at $902.3 million during Q3 2025, with a 5-year trough of $260.1 million in Q1 2021.
  • Over the past 3 years, Ani Pharmaceuticals' median Total Liabilities value was $446.8 million (recorded in 2023), while the average stood at $632.3 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Total Liabilities dropped by 7.45% in 2021 and then surged by 100.25% in 2025.
  • Ani Pharmaceuticals' Total Liabilities (Quarterly) stood at $412.9 million in 2021, then grew by 2.10% to $421.5 million in 2022, then climbed by 6.00% to $446.8 million in 2023, then soared by 91.39% to $855.2 million in 2024, then increased by 5.34% to $902.3 million in 2025.
  • Its Total Liabilities stands at $902.3 million for Q3 2025, versus $881.4 million for Q2 2025 and $849.0 million for Q1 2025.